| 胰升血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂治疗2型糖尿病临床疗效的观察 |
| |
| 引用本文： | 徐娜,金文波.胰升血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂治疗2型糖尿病临床疗效的观察[J].中华糖尿病杂志,2014(8):731-733. |
| |
| 作者姓名： | 徐娜 金文波 |
| |
| 作者单位： | 河南省南阳市中心医院内分泌科; |
| |
| 摘 要： | 目的 观察胰升血糖素样肽-1 （GLP-1）受体激动剂和二肽基肽酶-4（DPP-4）抑制剂对于治疗T2DM的临床疗效. 方法 将T2DM患者按随机数字表法分为DPP-4组和GLP-1组,每组各40例.26周后,观察两组治疗疗效及各项指标的变化. 结果 26周后,两组FPG及HbA1c均较治疗前下降（P＜0.05）,与DPP-4组比较,GLP-1组下降更明显. 结论 GLP-1治疗T2DM的疗效优于DPP-4,值得在临床上推广使用.
|
| 关 键 词： | 糖尿病 2型 二肽基肽酶-4 胰升血糖素样肽-1 |
The analysis of clinical effect of DPP-4 inhibitor versus GLP-1 receptor agonist treatment of type 2 diabetes |
| |
| XU Na,JIN Wen-bo.The analysis of clinical effect of DPP-4 inhibitor versus GLP-1 receptor agonist treatment of type 2 diabetes[J].CHINESE JOURNAL OF DIABETES MELLITUS,2014(8):731-733. |
| |
| Authors: | XU Na JIN Wen-bo |
| |
| Institution: | 1.Department of Endocrinology, Nanyang Central Hospital of Henan Province,Nanyang 473009, China;) |
| |
| Abstract: | Objective To observe the clinical effects of glucagon-like peptide-1 （GLP-1） receptor agonist versus sitagliptin dipeptidyl peptidase-4 （DPP-4） inhibitor for the treatment of type 2 diabetes mellitus （T2DM）.Methods Patients with type 2 diabetes were divided into the DPP-4 group （n=40） and GLP-1 group（n =40） according to random digits table.After 26 weeks,the curative effects and changes of each indicator in the two groups were observed.Results After 26 weeks of treatment,the FPG and HbA1 c of two groups were decreased as compared with those before treatment （P＜0.05）.And the HbA1c decrement of GLP-1 group is better than that of DPP-4 group（P＜0.05）.Conclusion The curative effect of GLP-1 is better than that of DPP-4 in the treatment of type 2 diabetes,thus GLP-1 is worth of popularizing in clinical use. |
| |
| Keywords: | Diabetes mellitus type 2 Dipeptidyl peptidase-4 （DPP-4） Glucagon-like peptide-1 （GLP-1） |
| 本文献已被 CNKI 维普 等数据库收录！ |
